-- 
Merck KGaA Acquires Rights to PI-2301 for Multiple Sclerosis

-- B y   R a j i v   S e k h r i
-- 
2011-09-19T06:34:29Z

-- http://www.bloomberg.com/news/2011-09-19/merck-kgaa-acquires-rights-to-pi-2301-for-multiple-sclerosis.html
Merck KGaA (MRK)  acquired worldwide
exclusive rights to PI-2301, an experimental drug for multiple
sclerosis, previously developed by Peptimmune Inc., Merck said
in an e-mailed statement today.  To contact the editor responsible for this story:
Rajiv Sekhri at 
 rsekhri1@bloomberg.net  